<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766866</url>
  </required_header>
  <id_info>
    <org_study_id>PE37</org_study_id>
    <nct_id>NCT04766866</nct_id>
  </id_info>
  <brief_title>sFlt1/PlGF and Selective Labor Induction to Prevent Preeclampsia at Term</brief_title>
  <acronym>PE37</acronym>
  <official_title>PE37: A Multicenter Randomized Trial of Screening With sFlt1/PlGF and Selective Labor Induction to Prevent Preeclampsia at Term</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Preeclampsia (PE) affects ~5% of pregnancies. Although improved obstetrical care has&#xD;
           significantly diminished associated maternal mortality, PE remains a leading cause of&#xD;
           maternal morbidity and mortality in the world.&#xD;
&#xD;
        -  Term PE accounts for 70% of all PE and a large proportion of maternal-fetal morbidity&#xD;
           related with this condition. Prediction and prevention of term PE remains unsolved.&#xD;
&#xD;
        -  Previously proposed approaches are based on combined screening and/or prophylactic&#xD;
           drugs, but these policies are unlikely to be implementable in many world settings.&#xD;
&#xD;
        -  Recent evidence shows that sFlt1-PlGF ratio at 35-37w predicts term PE with 80%&#xD;
           detection rate.&#xD;
&#xD;
        -  Likewise, recent studies demonstrate that induction of labor (IOL) from 37w is safe.&#xD;
&#xD;
        -  The investigators hypothesize that a single-step universal screening for term PE based&#xD;
           on sFlt1/PlGF ratio at 35-37w followed by IOL from 37w would reduce the prevalence of&#xD;
           term PE without increasing cesarean section rates or adverse neonatal outcomes.&#xD;
&#xD;
        -  The investigators propose a randomized clinical trial to evaluate the impact of a&#xD;
           screening of term PE with sFlt-1/PlGF ratio in asymptomatic nulliparous women at 35-37w.&#xD;
           Women will be assigned to revealed (sFlt-1/PlGF known to clinicians) versus concealed&#xD;
           (unknown) arms. A cutoff of &gt;90th centile will be used to define high risk of PE and&#xD;
           offer IOL from 37w.&#xD;
&#xD;
        -  If successful, the results of this trial will provide evidence to support a simple&#xD;
           universal screening strategy reducing the prevalence of term PE, which could be&#xD;
           applicable in most healthcare settings and have enormous implications on perinatal&#xD;
           outcomes and public health policies worldwide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Finding an effective prediction and prevention for term PE remains an unsolved challenge.&#xD;
      From previous recent evidence it seems clear that prediction very close to term may achieve a&#xD;
      high detection rate, but there is no evidence as to which strategy might be effective in&#xD;
      preventing PE in high-risk women. The investigators postulate that a solution that would be&#xD;
      applicable in most settings worldwide would require a simplified, pragmatic, approach. The&#xD;
      rationale of this proposal is that PE could be reduced with a single-step lab test screening&#xD;
      followed by induction of labor (IOL).&#xD;
&#xD;
      A single-step lab measure to detect PE. Combined algorithms using angiogenic factors with&#xD;
      Doppler ultrasound and maternal features seem to achieve the highest performance in detecting&#xD;
      pre-clinical PE. However, the need to train staff and change pregnancy care protocols renders&#xD;
      difficult generalization in high-resource and even more low-resource settings. On the&#xD;
      contrary, single lab tests can be more easily incorporated into the mainstream clinical&#xD;
      practice and provide a widespread solution for high-resource settings and specially&#xD;
      sub-optimal healthcare systems heavily affected by the consequences of term PE. Angiogenic&#xD;
      factors are the obvious candidate for these purposes. The sFlt1/PlGF ratio at 35-36w predicts&#xD;
      term PE with a DR of 82% and is a standardized lab test nowadays, realizable by ELISA with&#xD;
      widely available automated lab platforms. Normal values in late pregnancy have been reported&#xD;
      and are fairly similar among different populations. As preliminary research for this study,&#xD;
      the investigators have confirmed that the gestational-age adjusted normal values of&#xD;
      sFlt1/PlGF matched quite remarkably those previously published in different populations&#xD;
      across Europe. A one-step screening with sFlt1/PlGF would select a 5-10% of the population&#xD;
      with the highest risk for PE.&#xD;
&#xD;
      IOL at 37 weeks as an intervention in women at high-risk for PE. Previous trials based on&#xD;
      statins have failed to show a reduction of PE in high-risk women. IOL at 37 weeks is an&#xD;
      alternative to avoid PE in those high-risk women. IOL has consistently been demonstrated to&#xD;
      be safe ( ) and does not affect long-term maternal quality of life ( ). Both the HYPITAT and&#xD;
      the DIGITAT randomized trials showed that IOL did not increase caesarean rates or adverse&#xD;
      neonatal outcomes ( ). A recent large randomized trial in the US has shown that even in&#xD;
      low-risk women, universal IOL decreased cesarean section rates and was well accepted ( ).&#xD;
      While in low-risk pregnancies labour induction has been found to be beneficial from 39 weeks&#xD;
      (ARRIVE study), in women with placental-related conditions such as hypertension (HYPITAT) or&#xD;
      small-for-gestational age (DIGITAT) it is 37+ weeks when the trade-off between neonatal and&#xD;
      maternal benefits makes induction recommendable.&#xD;
&#xD;
      Therefore, the investigators hypothesize that a single-step universal screening for term PE&#xD;
      based on sFlt1/PlGF ratio at 35-36.6 w followed by IOL at 37w in those women found to be at&#xD;
      high risk might represent a feasible and reproducible strategy, applicable worldwide, to&#xD;
      reduce the prevalence of term PE without increasing cesarean section rates or adverse&#xD;
      neonatal outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, open-label randomized study with parallel groups.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Upon agreement to participate in this study, patients will be randomized to one of the following groups:&#xD;
• Intervention group or reveal group (sFlt-1/PlGF result known to clinicians). A ratio cutoff of &gt;p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Preeclampsia development</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with preeclampsia/total number participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal morbidity rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Composite including any of the following: (i) HELLP syndrome; (ii) Central nervous system dysfunction (eclampsia, Glasgow Coma Score &lt;13, stroke, reversible ischemic neurological deficit or cortical blindness); (iii) hepatic dysfunction; (iv) renal dysfunction; (v) respiratory dysfunction; (vi) cardiovascular dysfunction; (vii) placental abruption; or, (viii) a requirement for transfusion of blood products according to the total deliveries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Hospital stay</measure>
    <time_frame>6 weeks</time_frame>
    <description>Days of admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caesarean section rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>number of c-section / total deliveries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal complications rate</measure>
    <time_frame>18 weeks</time_frame>
    <description>Presence of placental abruptio, severe fetal growth restriction (defined as birth weight &lt;3rd centile), perinatal mortality, an Apgar score at 5-minute below 7.0, an umbilical artery pH below 7.10, need for respiratory support within 72 hours after birth neonatal intraventricular haemorrhage grade III/IV, necrotizing enterocolitis, periventricular leukomalacia, sepsis, bronchopulmonary dysplasia or hypoxic ischemic encephalopathy/total deliveries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal hospital stay</measure>
    <time_frame>18 weeks</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal experience</measure>
    <time_frame>12 weeks</time_frame>
    <description>Satisfaction score (PSS, STAI, WHO and Labor Agentry scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incurred costs</measure>
    <time_frame>6 weeks</time_frame>
    <description>Calculated costs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Cardiovascular risk</measure>
    <time_frame>6 months post-delivery</time_frame>
    <description>Maternal blood pressure and endothelial function 6-months postpartum/ participants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9132</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Intrauterine Growth Restriction</condition>
  <condition>Maternal Hypertension</condition>
  <condition>Neonatal Outcome</condition>
  <condition>Perinatal Death</condition>
  <arm_group>
    <arm_group_label>Non-intervention or non-reveal group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group or reveal group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A ratio cutoff of &gt;p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>sFlt1/PlGF screening in maternal blood at 35 to 37 weeks of gestation</intervention_name>
    <description>A ratio cutoff of &gt;p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation</description>
    <arm_group_label>Intervention group or reveal group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Nulliparous women&#xD;
&#xD;
          -  Singleton pregnancies&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  35.0-36.6 weeks of gestation&#xD;
&#xD;
          -  Maternal written consent form&#xD;
&#xD;
          -  Planned vaginal delivery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Any maternal or fetal complications that require labor induction before 38 weeks&#xD;
        according to local institutional protocols (including established preeclampsia).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elisa Llurba, MD; PhD</last_name>
    <phone>0034687743699</phone>
    <email>ellurba@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic Chantraine</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for the Care of Mother and Child</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ladislav Kofta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre of Postgraduate Medical Education, Obstetrics and Gynecology and Perinatal Medicine</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Kajdy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mina Comas, PhD</last_name>
      <email>minacomas.germanstrias@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Insular Materno Infantil</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Islas Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonor Valle</last_name>
      <email>leonorvalle@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Luís Delgado</last_name>
      <email>juanluisdelgado.tokos@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Llurba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toni Payà</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Maternitat del Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesc Figueras</last_name>
      <email>ffiguera@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesc Figueras</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Luis Bartha</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Tubau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfredo Perales</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Oros</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</investigator_affiliation>
    <investigator_full_name>Elisa Llurba</investigator_full_name>
    <investigator_title>Professor of Obstetric and Gynecology Universitat Autònoma de Barcelona</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia, angiogenic factors, perinatal death, induction of labour</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Perinatal Death</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT04766866/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

